Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01935492
What this trial is testing

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Borstkanker Onderzoek Groep 420
Not applicableLooking for participantsNCT07091019
What this trial is testing

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals 1,000
Testing effectiveness (Phase 2)Study completedNCT00094809
What this trial is testing

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Who this might be right for
Colon CancerColorectal CancerRectal Cancer
Amgen 252
Testing effectiveness (Phase 2)Looking for participantsNCT06367088
What this trial is testing

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple-negative Breast CancerCadonilimab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07045805
What this trial is testing

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Who this might be right for
Gastric Cancer (GC)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 66
Testing effectiveness (Phase 2)Study completedNCT03945773
What this trial is testing

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Who this might be right for
Locally Advanced or Metastatic Renal Cell Carcinoma
Ipsen 127
Early research (Phase 1)Ended earlyNCT01714037
What this trial is testing

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Who this might be right for
Non-small Cell Lung Cancer
Debiopharm International SA 82
Testing effectiveness (Phase 2)Looking for participantsNCT06394674
What this trial is testing

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Who this might be right for
Non-Small Cell Lung Cancer
Changhai Hospital 84
Not applicableStudy completedNCT05399329
What this trial is testing

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Who this might be right for
Breast Cancer
Pfizer 693
Early research (Phase 1)Study completedNCT00528281
What this trial is testing

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 18
Testing effectiveness (Phase 2)UnknownNCT05662813
What this trial is testing

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Who this might be right for
Non-small Cell Lung Cancer
West China Hospital 55
Not applicableStudy completedNCT07213076
What this trial is testing

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 350
Large-scale testing (Phase 3)Study completedNCT00003917
What this trial is testing

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Case Comprehensive Cancer Center 4
Large-scale testing (Phase 3)Not Yet RecruitingNCT07791732
What this trial is testing

Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)

Who this might be right for
Fallopian Tube CancerPrimary Peritoneal CancerHigh-Grade Serous Ovarian Cancer+1 more
Daiichi Sankyo 600
Early research (Phase 1)Study completedNCT00507091
What this trial is testing

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Who this might be right for
MetastaticColorectalAdenocarcinoma
Genzyme, a Sanofi Company 24
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Study completedNCT00051103
What this trial is testing

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Who this might be right for
Metastatic Breast CancerNeoplasms, Breast
GlaxoSmithKline
Testing effectiveness (Phase 2)Looking for participantsNCT04038502
What this trial is testing

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development 100
Testing effectiveness (Phase 2)Study completedNCT01954745
What this trial is testing

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Who this might be right for
Bile Duct CancerIntrahepatic CholangiocarcinomaCholangiocarcinoma of the Extrahepatic Bile Duct
Massachusetts General Hospital 19
Testing effectiveness (Phase 2)Study completedNCT00792025
What this trial is testing

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Institut Curie 80
Next Page